Amgen (NASDAQ:AMGN) Stock Gets Price Target Bump from Barclays

Amgen (NASDAQ:AMGN – Get Free Report) had its price objective raised by research analysts at Barclays from $400.00 to $430.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical research company’s stock. Barclays‘s target price points to a potential downside of 8.71% from the company’s current price.

A number of other research analysts have also weighed in on AMGN. Royal Bank Of Canada raised their price target on shares of Amgen from $430.00 to $470.00 and gave the company an “outperform” rating in a research note on Wednesday, November 4th. Morgan Stanley boosted their price objective on Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 4th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, October 18th. Citigroup increased their target price on Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Finally, Scotiabank raised their target price on Amgen from $500.00 to $530.00 and gave the company a “sector outperform” rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $425.69.

View Our Latest Analysis on AMGN

Amgen Price Performance

AMGN traded up $5.37 during midday trading on Monday, hitting $471.04. 147,659 shares of the company traded hands, compared to its average volume of 2,741,069. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The company has a market capitalization of $254.79 billion, a price-to-earnings ratio of 27.38, a PEG ratio of 3.24 and a beta of 0.43. Amgen has a 52-week low of $312.39 and a 52-week high of $483.99. The business has a 50 day simple moving average of $425.31 and a two-hundred day simple moving average of $381.17.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the business earned $5.64 earnings per share. On average, equities analysts forecast that Amgen will post 23.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amgen

Several hedge funds and other institutional investors have recently modified their holdings of AMGN. CSM Advisors LLC boosted its position in Amgen by 74.7% during the third quarter. CSM Advisors LLC now owns 1,719 shares of the medical research company’s stock worth $725,000 after acquiring an additional 735 shares during the last quarter. Cetera Investment Advisers grew its stake in Amgen by 0.4% during the 3rd quarter. Cetera Investment Advisers now owns 334,927 shares of the medical research company’s stock valued at $141,175,000 after acquiring an additional 1,383 shares in the last quarter. Empirical Finance LLC grew its stake in Amgen by 2.2% during the 3rd quarter. Empirical Finance LLC now owns 19,284 shares of the medical research company’s stock valued at $8,128,000 after acquiring an additional 419 shares in the last quarter. Jump Financial LLC purchased a new stake in Amgen during the 3rd quarter valued at about $14,833,000. Finally, Perennial Investment Advisors LLC raised its holdings in Amgen by 20.5% in the 3rd quarter. Perennial Investment Advisors LLC now owns 3,731 shares of the medical research company’s stock valued at $1,573,000 after acquiring an additional 635 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

About Amgen

(Get Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Recommended Stories

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.